Good news for SBP with the rights issue/capital raising. Maybe now the market will see the co with ethics approval for phase 2 trials granted it should have a much higher market cap.
The average market caps of the Aust biotech’s in phase 2 trials is 155m & with the principal of Kirke securities Grahame Kirke along with Russell Barnett joining the board maybe the market will take SBP seriously & re rate it.
I continue to hold long term.
SBP
solbec pharmaceuticals limited
Good news for SBP with the rights issue/capital raising. Maybe...
Add to My Watchlist
What is My Watchlist?